

PROCEDURE / METHOD:

Digistain use of spectrometry in cancer diagnostics, through biopsy imaging and it analyses wavelengths that are absorbed by nucleic acids and cell proteins. This imaging approach enables to measure chemical concentrations associated with malignancy, precisely determines the characteristics of cancer cells and quantify validated pathology markers correlated to tumor proliferation.

This technology also captures a unique spectral signature from each biopsy and performs analysis on over 10,000 data points per biopsy. Using this data, Digistain’s proprietary AI identifies risk profiling patterns and computes an accurate risk score – the Digistain Prognostic Score.

FINDINGS OF DIGISTAIN TEST:

Marker	Score	Recurrence Risk
Digistain Prognostic Risk Score	2.03	HIGH
10yr Recurrence with Endocrine Therapy only	>35%	HIGH

RESULT:

A 2.03 Digistain Prognostic Score measuring chromosome instability indicated a HIGH RISK and 35% chance of developing distant metastasis based on a 10 Year Risk of Recurrence if treated with endocrine therapy alone. Patient will require chemotherapy based on the prognostic score values.